Sugi Predict

Sugi Predict / Compounds / SCHEMBL2026360

SCHEMBL2026360

SCHEMBL2026360

CN[C@H]1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 1/20 0.55
▸ USP30 Q70CQ3 3/20 0.53
▸ CA1 P00915 2/20 0.52
▸ CA2 P00918 2/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ HPGD P15428 1/20 0.50
▸ HDAC4 P56524 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ PARP1 P09874 1/20 0.45
▸ FPR3 P25089 1/20 0.45
▸ FPR2 P25090 1/20 0.45
▸ BRD4 O60885 1/20 0.43
▸ PREP P48147 1/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL556321 1.00 EPHX1 (0.55) EPHX1USP30CA1CA2MEN1
SCHEMBL2024838 1.00 EPHX1 (0.55) EPHX1USP30CA1CA2MEN1
SCHEMBL6758417 0.95 EPHX1 (0.57) EPHX1USP30CA1CA2MEN1
SCHEMBL6758420 0.95 EPHX1 (0.57) EPHX1USP30CA1CA2MEN1
SCHEMBL2069710 0.95 EPHX1 (0.57) EPHX1USP30CA1CA2MEN1
SCHEMBL2500606 0.90 EPHX1 (0.57) EPHX1USP30MEN1ALDH1A1MAPT
SCHEMBL671402 0.90 EPHX1 (0.57) EPHX1USP30MEN1ALDH1A1MAPT
SCHEMBL189361 0.90 EPHX1 (0.57) EPHX1USP30MEN1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL2495441 0.89 EPHX1 (0.56) EPHX1USP30MEN1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL2500609 0.89 EPHX1 (0.56) EPHX1USP30MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724443-A1 PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE Acrivon Therapeutics, Inc. (US) 2026-04-15 — — EP disclosed
EP-4674484-A2 THIENOPYRROLE COMPOUNDS Gilead Sciences, Inc. (US) 2026-01-07 — — EP disclosed
EP-4656201-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2025-12-03 — — EP disclosed
EP-4643954-A2 NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2025-11-05 — — EP disclosed
EP-4291562-B1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES INC (US) 2025-09-10 — — EP disclosed
US-20250051306-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-02-13 — — US disclosed
WO-2024254490-A1 PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE ACRIVON THERAPEUTICS, INC. (US) 2024-12-12 — — WO disclosed
EP-3681877-B1 PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF HANMI PHARMACEUTICAL CO LTD (KR) 2024-10-16 — — EP disclosed
CN-112638910-B New heterocyclic amine derivatives and pharmaceutical compositions containing the same 株式会社大熊制药 2024-06-11 — — CN disclosed
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 — — US disclosed
EP-2516425-B1 AMINOPYRIMIDINE KINASE INHIBITORS JASCO PHARMACEUTICALS LLC (US) 2015-09-02 — — EP disclosed
US-9079866-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 — — US disclosed
US-20150105370-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-16 — — US disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 — — US disclosed
US-20140080799-A1 Aminopyrimidine Kinase Inhibitors Jasco Pharmaceuticals, LLC (US) 2014-03-20 — — US disclosed
WO-2013163466-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2013-10-31 — — WO disclosed
US-8563539-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2013-10-22 — — US disclosed
US-20110152235-A1 Aminopyrimidine Kinase Inhibitors Jasco Pharmaceuticals, LLC (US) 2011-06-23 — — US disclosed
US-20100104659-A1 BENZOPYRANOPYRAZOLES 4SC AG (DE) 2010-04-29 — — US disclosed
CN-101578275-A Anilinopiperazine derivatives and methods of use thereof SCHERING CORP (US) 2009-11-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051306-A1 RAS INHIBITORS KRAS, NRAS, HRAS EPHX1 2887/4885USP30 1265/4885CA1 4685/4885
US-11739074-B2 Ras inhibitors KRAS, NRAS, HRAS EPHX1 2296/4885USP30 1880/4885CA1 4562/4885
US-20140080799-A1 Aminopyrimidine Kinase Inhibitors PIM1, PIM2, PIM3 EPHX1 4680/4885USP30 3442/4885CA1 3871/4885
US-20150105370-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS SSB, TLR7, TLR8 EPHX1 4121/4885USP30 4190/4885CA1 4645/4885
US-20110152235-A1 Aminopyrimidine Kinase Inhibitors PIM1, PIM2, PIM3 EPHX1 4696/4885USP30 3427/4885CA1 3842/4885
US-20100104659-A1 BENZOPYRANOPYRAZOLES BAX, BCL2, BAD EPHX1 3284/4885USP30 2888/4885CA1 3275/4885
US-20140221311-A1 FLAP MODULATORS PGF, FEN1, TBXA2R EPHX1 503/4885USP30 2569/4885CA1 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.